二甲双胍不耐受T2DM患者应用沙格列汀治疗的效果分析

Analysis of the effect of saxagliptin in patients with metformin intolerance T2DM

[目的]探讨二甲双胍不耐受T2DM患者应用沙格列汀治疗的效果。[方法]回顾性分析2018年1月至2018年12月我院收治的120例二甲双胍治疗不耐受的T2DM患者临床资料,按治疗方法分为实验组和对照组,各60例。对照组予以基础治疗+格列美脲治疗,实验组予以基础治疗+沙格列汀治疗,治疗时间均为12周。比较2组治疗效果、治疗前后血糖变化及C肽水平,观察2组FINS水平、胰岛细胞功能指数、药物不良反应的发生情况。[结果]实验组治疗有效率高于对照组,差异有统计学意义(P<0.05);经治疗后实验组患者FBG、PBG、HbA1c低于对照组,F-C肽和P-C肽高于对照组,差异有统计学意义(P<0.05);实验组FINS水平、胰岛细胞功能指数高于对照组,差异有统计学意义(P<0.05);实验组治疗药物不良反应发生率低于对照组,差异有统计学意义(P<0.05)。[结论]沙格列汀用于治疗二甲双胍不耐受T2DM患者疗效确切,可有效降血糖和改善胰岛素细胞功能,且不良反应相对较少。

[Objective]To investigate the effect of sagliptin in patients with metformin intolerance T2 DM. [Methods]The clinical data of 120 patients with metformin treatment intolerance in T2 DM treated in our hospital from January 2018 to December 2018 were retrospectively analyzed. They were divided into experimental group and control group, with 60 cases in each group. The control group was treated with basic treatment + glimepiride, and the experimental group was treated with basic treatment + sagliptin. The treatment time was 12 weeks. The treatment effects, blood glucose changes and C-peptide levels before and after treatment were compared between the two groups, and the levels of FINS, islet cell function index, and adverse drug reactions were observed in the two groups. [Results]The treatment efficiency of the experimental group was higher than that of the control group, and the difference was statistically significant(P<0.05). After treatment, the patients in the experimental group had lower FBG, PBG, and HbA1 c than the control group, and FC peptide and PC peptide were higher than the control group. There was statistical significance(P<0.05);the level of FINS and islet cell function index in the experimental group were higher than those in the control group, and the differences were statistically significant(P<0.05);the incidence of adverse drug reactions in the experimental group was lower than that in the control group, and the differences were: Statistical significance(P<0.05). [Conclusion]Saxagliptin is effective in treating metformin intolerant T2 DM patients. It can effectively lower blood glucose and improve insulin cell function with relatively few adverse reactions.